Eversense 365 and iLet Bionic Pancreas: Price, How It Works, and First Take

Eversense 365 and iLet Bionic Pancreas: Price, How It Works, and First Take

Senseonics and Beta Bionics commercially launched the iLet Bionic Pancreas integrated with the Eversense 365 continuous glucose monitoring system on November 16, 2026. It pairs the only glucose sensor designed to last a full year with a pump that decides every insulin dose on its own, no carb counting and no manual correction boluses. No price or insurance details were disclosed in the launch announcement.

What Is the Eversense 365 and iLet System?

The system has two halves that now work as one. Eversense 365, made by Senseonics of Germantown, Maryland, is an implantable continuous glucose monitor, or CGM. A small sensor is inserted under the skin by a healthcare provider, and a removable smart transmitter worn on the skin above it sends real-time glucose data to a phone app or to an automated insulin delivery system. One sensor is designed to last up to 365 days.

The iLet Bionic Pancreas, made by Beta Bionics of Irvine, California, is the dosing half. It is a fully adaptive automated insulin delivery system that uses CGM data and a proprietary algorithm to determine and deliver insulin doses by itself. Beta Bionics says its dosing algorithm is the first FDA cleared algorithm that autonomously determines every insulin dose.

Together, the two devices close the loop. The sensor measures glucose, the pump doses insulin from those measurements, and the user does not count carbohydrates or enter correction boluses. The user does still need to be carb aware, which is the companies own footnote on the announcement.

I have not worn an Eversense sensor, and no hands-on test of this integrated system exists yet. The launch was announced on November 16, 2026, and this article reports what the announcement actually says, what the sensor math shows against the two leading patch CGMs, and who this system is really for. The Biohack covers metabolic health technology because glucose data is the most direct window most people have into their own metabolism, and a one year sensor plus fully automated dosing is the biggest change in that hardware in years.

What Did Senseonics and Beta Bionics Actually Announce?

The commercial launch was announced on Monday, November 16, 2026, in a joint GlobeNewswire release from Germantown, Maryland, and Irvine, California. Senseonics Holdings trades on NASDAQ as SENS. Beta Bionics trades as BBNX. The release was carried the same day by Morningstar, TradingView, and TML News.

The launch closes a schedule the companies set in public. Senseonics and Beta Bionics announced their partnership in September 2026 and committed to launching the integrated system in the fourth quarter of 2026. The November 16 launch meets that commitment, about two months after the partnership was announced.

Brian Hansen, Chief Commercial Officer of Senseonics, said the launch gives users another automated insulin delivery option and expands choice around the worlds first and only one year CGM. Mark Hopman, Chief Commercial Officer of Beta Bionics, said integrating the two technologies combines an accurate long term sensing option with an automated system that makes 100 percent of insulin dosing decisions.

The companies also committed to a next integration: Eversense 365 with Mint, Beta Bionics tubeless patch pump. No date was given for that launch.

How Does the Eversense 365 Sensor Work?

Eversense 365 is different from every other CGM on the market in one basic way: the sensor lives under the skin instead of stuck on top of it. A healthcare provider inserts a small sensor under the skin of the upper arm. A removable smart transmitter sits on the skin above the sensor and powers it, reads it, and sends the glucose data to a phone app or to a connected insulin pump.

The sensor measures glucose in interstitial fluid, the fluid between cells just under the skin, and reports a reading every few minutes around the clock. The system is indicated for continually measuring glucose for up to 365 days, and it can replace fingerstick blood glucose measurements for diabetes treatment decisions.

There are two catches to that fingerstick claim. First, fingerstick calibration is still required primarily one time per week after day 14. Second, a fingerstick is still needed when symptoms do not match the CGM reading, or when taking medications of the tetracycline class. So the sensor does not eliminate fingersticks entirely; it cuts them to about one a week after the first two weeks.

Eversense 365 is cleared in the United States and approved in Europe for people with diabetes aged 18 years and older, and it is available by prescription only. It is available in the United States and in select European markets.

The one year sensor is not new by itself. The FDA cleared Eversense 365 as a 365 day system on September 17, 2024. What is new on November 16, 2026, is the commercial integration with the iLet pump, which turns the long life sensor into one half of a fully automated dosing system.

The published accuracy evidence for the Eversense platform comes from the PRECISE II trial, cited in the launch release. That study enrolled 90 adults with diabetes at 8 clinical centers, collected more than 16,000 comparative glucose data points, and reported a mean absolute relative difference, or MARD, of 8.8 percent across the 40 to 400 mg/dL range against laboratory blood reference values. Note the context: PRECISE II tested the earlier 90 day Eversense sensor, not the 365 day sensor. MARD is the standard accuracy score for CGMs, and lower is better. A MARD of 8.8 percent sits in the same band as the leading patch CGMs.

How Does the iLet Bionic Pancreas Work?

The iLet is an insulin pump with a closed loop brain. It takes the glucose stream from the CGM and runs it through a proprietary adaptive algorithm that decides how much insulin to deliver, and when, without the user entering carbohydrate counts or correction doses. The companies describe it as fully adaptive: the algorithm learns and adapts to individual insulin needs over time.

That is a real difference from most automated insulin delivery systems, which still ask the user to announce meals and estimate carbohydrates. The iLet asks only that the user be carb aware, meaning roughly aware of the carbohydrate content of what they eat, without counting grams or entering numbers.

The practical result, if the system works as described, is that diabetes management becomes mostly supervision. The user wears the sensor and the pump, checks the app, and changes the sensor once a year. The daily work of dosing decisions moves from the person to the algorithm.

The limit is that the iLet still needs a sensor it trusts. Fewer sensor changes and fewer disruptive false alerts than traditional CGMs are part of the pitch, and the year long sensor is what makes the combination distinctive. A pump that doses by itself is only as good as the glucose data feeding it, and a sensor that stays in place for 365 days removes 35 sensor swaps a year from that equation.

Who Can Get the Eversense 365 and iLet System?

The system is for people with diabetes who use insulin, aged 18 years and older, in the United States or select European markets. It is prescription only, and the sensor must be inserted by a healthcare provider. That insertion step is the main access difference from patch CGMs: a Dexcom G7 or FreeStyle Libre 3 is applied by the user at home in minutes, while an Eversense sensor requires a clinic visit for insertion and another for removal and replacement once a year.

It is not for people without diabetes who want a metabolic dashboard. The biohacking audience that wears CGMs to tune meals and workouts uses over the counter systems such as Dexcom Stelo, and the Eversense 365 plus iLet combination is a medical system for insulin requiring diabetes. The sensor alone is the part biohackers would want, but it is prescription only and it is sold as a diabetes device, not a wellness wearable.

It is also not a system for children. The 18 years and older indication excludes pediatric use. And anyone taking tetracycline class medications should know the system requires fingerstick checks while on those drugs, because tetracycline interferes with the sensor chemistry.

Getting started runs through the companies joint page, Eversense365+iLet, and through a clinician who can prescribe the system and perform the insertion. The launch release gives no waitlist, no rollout schedule by region, and no timeline for how fast new patients can be scheduled.

How Much Does the Eversense 365 and iLet System Cost?

The companies provided no pricing or insurance coverage details in the November 16 announcement. That is the single biggest unanswered question about the launch, and the coverage of the announcement flags it directly: the two questions patients ask first, what does it cost and will my plan pay for it, were left for the rollout itself.

That silence matters because the cost structure is genuinely different from patch CGMs. A patch CGM is a consumable bought by the sensor, and its price is public. An Eversense system is a procedure plus hardware: a sensor, a transmitter, and a clinician insertion, with the sensor replaced once a year. The per year cost depends on the sensor price, the transmitter price, the insertion fee, and what insurance covers, and none of those four numbers is public yet.

What can be priced today is the comparison. The sensor math below prices the two leading patch CGMs at cash pay retail, so the size of the gap the Eversense system has to beat is visible even before its own price is published.

What We Found When We Ran the Sensor Math: The Numbers

Quotable summary: One Eversense 365 sensor lasts 365 days, while a Dexcom G7 user needs about 35 sensors a year and a FreeStyle Libre 3 user needs about 26, and at cash retail those patch sensors cost about $4,800 and about $3,064 a year.

Here is the sensor comparison we compiled from the November 16 launch release and current Diabetic Warehouse retail listings:

  • Eversense 365: 1 sensor per year, 365 day wear, inserted by a healthcare provider, about 1 fingerstick calibration per week after day 14, or about 51 fingersticks a year
  • Dexcom G7: 10 day wear plus a 12 hour grace period, or 10.5 days total, which is 365 divided by 10.5, or about 35 sensors a year; $139.99 per sensor, or $399.99 for a 3 pack, which is about $4,800 a year at the 3 pack price
  • FreeStyle Libre 3: 14 day wear, which is 365 divided by 14, or about 26 sensors a year; $130 per sensor, or $235 for a 2 pack, which is about $3,064 a year at the 2 pack price
  • Sensor changes avoided: Eversense saves about 34 sensor applications a year against the G7 and about 25 against the Libre 3
  • Cash cost gap between the patch systems: the G7 costs about $1,736 a year more than the Libre 3 at these retail prices, or about 57 percent more
  • Fingerstick calibrations: Eversense needs about 51 a year, while the G7 and Libre 3 need zero routine calibrations
  • Insertion visits: Eversense needs 1 clinic visit a year for sensor replacement, while patch CGMs need zero visits and are applied at home
  • Accuracy benchmark: the published PRECISE II trial of the earlier 90 day Eversense sensor reported a MARD of 8.8 percent; the G7 and Libre 3 publish MARD figures in the same high 7 to low 9 percent band
  • Coverage audit: 3 independent outlets reported the launch on November 16, 2026, including the GlobeNewswire release carried by Morningstar and TradingView, plus TML News

The math cuts both ways. On sensor changes, Eversense wins by an enormous margin: 1 against 35, and 1 against 26. On fingersticks, it loses: about 51 a year against zero for the patch systems, because the implanted sensor still needs a weekly calibration check. On clinic visits, it loses by one visit a year against zero, because the sensor has to be inserted and removed by a clinician. Whether the trade is worth it depends on what the sensor and the procedure cost, and that number is still unpublished.

How Does It Compare With Dexcom G7 and FreeStyle Libre 3?

The Dexcom G7 is the accuracy and alerts leader among patch CGMs. Its sensor is an all in one unit, sensor plus transmitter in one disposable, worn for 10 days plus a 12 hour grace period. It needs no routine calibration and no separate transmitter to charge or manage. Its weakness in this comparison is churn: about 35 sensors a year, each one a fresh application, a fresh warm up, and a fresh chance for a sensor to fail early or fall off.

The FreeStyle Libre 3 is the low cost, long wear patch option. Its sensor lasts 14 days, needs no fingerstick calibration, and costs about $130 per sensor at cash retail, or about $3,064 a year in 2 packs. Its weakness is that it is a sensor only: it does not dose insulin, and pairing it with a pump means a separate automated insulin delivery system with its own setup.

The Eversense 365 plus iLet combination is the only one of the three that doses insulin by itself with no meal announcements. Its sensor lasts 36.5 times longer than a G7 sensor and 26 times longer than a Libre 3 sensor. Its weaknesses are the clinic insertion, the weekly fingerstick calibration, the 18 and older prescription only restriction, and the unpublished price.

For a person with type 1 diabetes who already uses a pump, the honest comparison is not sensor against sensor. It is system against system: Eversense plus iLet against a G7 or Libre 3 paired with a Tandem or Medtronic automated system. On that comparison, the Eversense combination wins on sensor changes and on meal announcements, and loses on insertion visits and calibration fingersticks.

What Is the Mint Pump, and What Comes Next?

Mint is Beta Bionics tubeless patch pump, and the companies have committed to integrating Eversense 365 with it in the future. No date was given. A tubeless patch pump removes the tubing that the iLet uses today, which matters for people who find a tubed pump awkward under clothing or during exercise and sleep.

The Mint integration is the second act of this launch, not the first. The November 16 announcement is the tubed iLet version. Anyone choosing the system today should assume the Mint version arrives on an unannounced schedule, and should not wait for it if they need automated dosing now.

The wider direction is clear: CGM hardware is splitting into two paths. One path is disposable and consumer, led by over the counter patch sensors for people without diabetes. The other path is implanted and clinical, led by Eversense, for people whose diabetes demands a sensor that never comes off. The iLet integration is the first time the implanted path has had a fully automated pump attached to it.

What Are the Trade-Offs?

The trade-offs are concrete and worth stating plainly. The sensor is implanted, which means a minor procedure with a clinician, a small incision, and a removal procedure a year later. The transmitter is removable and rechargeable, and it has to stay on the skin above the sensor with adhesive, so the system is not invisible. The sensor needs a fingerstick about once a week after day 14, which is more fingersticks than a patch CGM user does in a year. The system is prescription only, for adults, and it is not available to children or to people without diabetes. The price is unpublished, and insurance coverage is unconfirmed.

Against that, the system removes the single most annoying part of CGM life, which is changing sensors. Thirty five sensor changes a year is a real burden: each one is an application, a warm up period, and a small risk of failure. One sensor a year is a different life. And the iLet removes the second most annoying part, which is deciding insulin doses and counting carbohydrates at every meal.

This article is information, not medical advice. Anyone considering the system should talk to their diabetes clinician about whether an implanted sensor and a fully automated pump fit their diabetes, their lifestyle, and their insurance.

Frequently Asked Questions

What is the Eversense 365 and iLet system?

It is the commercial integration, launched November 16, 2026, of the Eversense 365 implantable CGM, whose single sensor lasts up to 365 days, with the iLet Bionic Pancreas, a pump whose algorithm autonomously determines every insulin dose from the CGM data.

How much does the Eversense 365 and iLet system cost?

No price was disclosed in the November 16, 2026, launch announcement, and no insurance coverage details were provided. For comparison, a Dexcom G7 costs about $4,800 a year and a FreeStyle Libre 3 about $3,064 a year at cash retail for sensors alone.

Who can use the Eversense 365 and iLet system?

People with diabetes aged 18 years and older who use insulin, in the United States or select European markets. It is prescription only, and the sensor must be inserted by a healthcare provider.

Does the Eversense 365 sensor really last a full year?

Yes, by design. One sensor is indicated for continually measuring glucose for up to 365 days. The FDA cleared the 365 day system on September 17, 2024. The sensor is replaced once a year in a clinic visit.

Do you still need fingersticks with Eversense 365?

Yes, about one a week. Fingerstick calibration is required primarily one time per week after day 14, plus whenever symptoms do not match the CGM reading or while taking tetracycline class medications. That is about 51 fingersticks a year, against zero routine calibrations for the Dexcom G7 and FreeStyle Libre 3.

What is the Mint pump?

Mint is Beta Bionics tubeless patch pump. Senseonics and Beta Bionics have committed to integrating Eversense 365 with Mint in the future, with no date announced. The November 16, 2026, launch pairs Eversense 365 with the tubed iLet pump.

Does the iLet really dose insulin without carb counting?

Yes, with one footnote. The iLet algorithm autonomously determines and delivers insulin doses without carb counting or manual correction boluses, but the user must be carb aware. Beta Bionics says its algorithm is the first FDA cleared algorithm that autonomously determines every insulin dose.

Related Reading

Sources: Senseonics and Beta Bionics joint GlobeNewswire release, November 16, 2026, via Morningstar; TML News, November 16, 2026; TradingView News, November 16, 2026; Diabetic Warehouse Dexcom G7 and FreeStyle Libre 3 listings, accessed November 17, 2026; FDA Devices at FDA, Eversense PMA records; Senseonics regulatory filing on Eversense 365 365-day approval, September 17, 2024; Christiansen et al., PRECISE II, Diabetes Technology and Therapeutics, 2018.